Thyroid Disease–Induced Hepatic Dysfunction: A Clinical Puzzle

Chimaobi M. Anugwom, MD1, and Thomas M. Leventhal, MD1

1Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN

ABSTRACT

The diagnostic evaluation of an individual with clinical and laboratory evidence of thyroid dysfunction in the setting of acute liver injury is crucial. There is a complex relationship between the thyroid and the liver, and so, it requires a careful elucidation of the inciting disease process before instituting a treatment plan. We discuss a patient who had presented with coagulopathy, encephalopathy, and laboratory evidence of acute liver injury, hence adjudged to have developed drug-induced acute liver failure and transferred for liver transplant evaluation. She was found to have liver dysfunction from uncontrolled thyroid disease, with immediate and rapid improvement after controlling severe hyperthyroidism.

INTRODUCTION

There is a well-known physiologic and pathologic relationship that exists between the liver and the thyroid gland. For this reason, the diagnostic evaluation of an individual with clinical and laboratory evidence of thyroid dysfunction in the setting of acute liver injury is crucial. It requires a careful elucidation of the inciting disease process before instituting a treatment plan. Here, we present a patient, adjudged to have developed drug-induced acute liver failure, who was found to have liver dysfunction from uncontrolled thyroid disease.

CASE REPORT

A 66-year-old woman with type 2 diabetes mellitus, atrial fibrillation on warfarin, as well as a recent diagnosis of Graves disease (positive thyroid-stimulating immunoglobulins and radioactive iodine uptake of 99%) was transferred to our facility with a diagnosis of drug-induced liver injury with resultant acute liver failure. She had initially presented with several weeks of malaise after being started on methimazole for her Graves disease, and she had taken this medication for only 4 days. Initial laboratory findings included markedly elevated liver transaminases, and her international normalized ratio (INR) was also high (Figures 1 and 2). Although she was being assessed and stabilized in the emergency department, she developed rapid deterioration of her mental status with lethargy, weakness, and progressed to frank confusion and somnolence. This led to urgent endotracheal intubation to ensure airway protection. To evaluate her confusion, an magnetic resonance imaging of the brain was obtained which did not show any acute intracranial pathology but noted findings suggesting chronic small vessel ischemic disease and mild diffuse cerebral atrophy. Based on the findings of coagulopathy and progressive encephalopathy in the setting of acute liver injury, she was diagnosed as having acute liver failure, N-acetylcysteine was started, and she was transferred to our transplant center for evaluation for liver transplantation.

Her medications were reviewed thoroughly, and the possibility of liver injury secondary to methimazole was entertained, as this was a new medication, so it was initially discontinued. On evaluation, she was afebrile but in atrial fibrillation with a heart rate of 118. She was initially hypotensive at 86/49 mm Hg. She was believed to have a Burch-Wartofsky Point Scale of 55, thus highly suggestive of severe thyrotoxicosis/thyroid storm. A comprehensive etiological workup was undertaken which yielded a negative antinuclear antibody and anti-smooth muscle antibody; negative viral serology for hepatitis A, B, and C, human immunodeficiency virus, and herpes simplex virus. She had a normal creatine kinase, and her serum acetaminophen and salicylate levels were below detectable range. She underwent a urine toxicology screen that was negative for alcohol and other drugs. A complete abdominal ultrasound with
Doplers was notable for a grossly normal liver with mild steatosis but no structural or vascular abnormalities. A portable chest radiograph noted mild pulmonary edema and cardiomegaly. A transthoracic echocardiogram was obtained as well, and this was significant for a left ventricular ejection fraction of 36%, with an enlarged right ventricle, moderately reduced right ventricular function, and a dilated inferior vena cava. Her thyroid function tests revealed undetectable thyroid-stimulating hormone and elevated free thyroxine hormones (free T4 and T3) (Figure 3). A diagnosis of thyrotoxicosis was made with resultant congestive cardiac failure and subsequent congestive hepatopathy. She was started on high-dose intravenous methylprednisolone and restarted on her methimazole. She improved clinically and had laboratory normalization of her INR and liver tests. She was ultimately discharged, clinically stable, to follow-up in the outpatient endocrinology clinic.

**DISCUSSION**

Hepatocyte activity is dependent on the regulatory function of thyroid hormones, and the liver plays a major role in the metabolism of these hormones, consequently affecting the systemic endocrine effects of the thyroid gland. The pathologic relationship between the liver and the thyroid gland has many facets because a myriad of liver diseases have been linked with thyroid disease and vice versa. Autoimmune hepatitis and primary biliary cholangitis have both been associated with autoimmune thyroiditis and Graves disease. Furthermore, hepatitis C virus (HCV) infection has also been linked with thyroid dysfunction as well—the presence of HCV seropositivity has been documented to coexist with development of thyroid autoimmunity and hypothyroidism. In addition, before the era of direct-acting antivirals in the treatment of HCV, interferon has been postulated to induce a direct toxic effect on thyroid follicular cells as well as cause autoimmune dysfunction. Our patient was therefore evaluated for primary liver diseases that share known associations with Graves disease and was negative for HCV infection, primary biliary cholangitis, and autoimmune hepatitis.

Thyroid dysfunction is treated with medications that may also cause hepatocellular or cholestatic liver injury. Propylthiouracil and methimazole have been known to cause transient, asymptomatic elevations in serum aminotransferase levels in the first 3 months of therapy, and the pattern of injury is typically hepatocellular. Cases of moderately severe cholestatic or mixed hepatitis have also been described and sometimes can progress to acute liver failure, which has necessitated liver transplantation or lead to death. The putative mechanism of this type of liver injury is an immunological reaction to a metabolic by-product of the medication. The possibility of liver injury secondary to methimazole was entertained, leading to stoppage of the medication on initial presentation. Our patient had been on this medication for less than 5 days, and it was hypothesized that the likelihood of drug-induced liver injury was low in this case.

Atrial fibrillation with a rapid ventricular rate on admission, a transthoracic echocardiogram was notable for significant right.

**Figure 1.** Trend of liver enzymes during hospitalization.
and left heart failure, with ventricular enlargement and decreased ejection fraction. The cardiovascular effect of thyroid dysfunction, as was apparent in our patient, has been shown to occur and may lead to liver dysfunction in multiple ways. Increased myocellular contraction, increased oxygen demand, increased preload, and decreased afterload may lead to

Figure 2. Trend of total bilirubin and international normalized ratio during hospitalization. INR, international normalized ratio.

Figure 3. Trend of serum-free thyroxine during hospitalization.
Informed consent could not be obtained from the patient despite several attempts. All identifying information has been removed from this case report to protect patient privacy.

Received May 30, 2020; Accepted October 4, 2020

REFERENCES

1. Mendel CM, Cavaliere RR, Weisger BA. Uptake of thyroxine by the perfused rat liver: Implications for the free hormone hypothesis. Am J Physiol 1988;255(2 Pt 1):E110–9.

2. Malik R, Hodgson H. The relationship between the thyroid gland and the liver. QJM 2002;95(9):559–69.

3. Zeniya M. Thyroid disease in autoimmune liver diseases [in Japanese]. Nihon Rinsho 1999;57(8):1882–7.

4. Floreani A, Mangini C, Reig A, et al. Thyroid dysfunction in primary biliary cholangitis: A comparative study at two European centers. Am J Gastroenterol 2017;112(1):114–9.

5. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des 2008;14(17):1678–85.

6. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;158(13):1445–8.

7. Mazzotti G, Sorvillo F, Piscopo M, et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: A prospective study. J Clin Endocrinol Metab 2005;90(7):4138–44.

8. Williams KY, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned? J Clin Endocrinol Metab 1997;82(6):1727–33.

9. Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: A single-center retrospective study. Am J Gastroenterol 2001;96(1):165–9.

10. Mikhail NE. Methimazole-induced cholestatic jaundice. South Med J 2004; 97(2):178–82.

11. Hammond HK, White FC, Buxton IL, Saltstein P, Brunton LL, Longhurst JC. Increased myocardial beta-receptors and adrenergic responses in hyperthyroid pigs. Am J Physiol 1987;252(2 Pt 2):H283–90.

12. Ertel S, Cicero AF. Hyperthyroidism and cardiovascular complications: A narrative review on the basis of pathophysiology. Arch Med Sci 2013;9(5):944–52.

13. Wu HH, Guo XH, Gao YM. Clinical features of thyrotoxic heart disease: Analysis of 75 cases [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87(4):262–4.

14. Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (N Y) 2011;7(5):337–9.

15. Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: Clinical, hemodynamic, and histologic characterizations and correlations. Hepatology 2003; 37(2):393–400.

16. Carroll R, Mat NW, Davidson DJ, et al. Cardiac hepatopathy: Clinical, hemodynamic, and histologic characterizations and correlations. Hepatology 2003; 37(2):393–400.

17. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. EndocrinoMetab Clin North Am 2006;35(4):663–86, vii.

DISCLOSURES

Author contributions: Both authors contributed equally to this manuscript. TM Leventhal is the article guarantor.

Financial disclosure: None to report.